Dusquetide TFA(Synonyms: SGX942 TFA)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Dusquetide TFA (Synonyms: SGX942 TFA)

Dusquetide (SGX942) TFA 是第一类天然防御调节因子 (IDR)。Dusquetide TFA 通过与 p62 结合调节 PAMPs 和 DAMPs 的天然免疫应答。Dusquetide TFA 在减轻炎症和增加细菌感染清除方面都显示出活性。

Dusquetide TFA(Synonyms: SGX942 TFA)

Dusquetide TFA Chemical Structure

规格 价格 是否有货 数量
1 mg ¥2200 In-stock
5 mg ¥5600 询价
10 mg ¥9500 询价
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

生物活性

Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection[1]. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns

体内研究
(In Vivo)

Dusquetide (SGX942) TFA (25 mg/kg; i.v.; days 0, 4, 7, 10, and 14) shows no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female nude mice (MCF-7 tumor xenografts)[1]
Dosage: 25 mg/kg
Administration: I.v.; days 0, 4, 7, 10, and 14
Result: Showed no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation.

Clinical Trial

分子量

667.72

Formula

C27H48F3N9O7

Sequence

{Arg}{Ile}{Val}{Pro}{Ala}-NH2

Sequence Shortening

RIVPA-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

参考文献
  • [1]. Kudrimoti M, et al. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016 Dec 10;239:115-125.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Dusquetide(Synonyms: SGX942)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Dusquetide (Synonyms: SGX942)

Dusquetide (SGX942) 是第一类天然防御调节因子 (IDR)。Dusquetide 通过与 p62 结合调节 PAMPs 和 DAMPs 的天然免疫应答。Dusquetide 在减轻炎症和增加细菌感染清除方面都显示出活性。

Dusquetide(Synonyms: SGX942)

Dusquetide Chemical Structure

CAS No. : 931395-42-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Dusquetide 的其他形式现货产品:

Dusquetide TFA

生物活性

Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection[1]. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns

体内研究
(In Vivo)

Dusquetide (SGX942) (25 mg/kg; i.v.; days 0, 4, 7, 10, and 14) shows no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female nude mice (MCF-7 tumor xenografts)[1]
Dosage: 25 mg/kg
Administration: I.v.; days 0, 4, 7, 10, and 14
Result: Showed no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation.

Clinical Trial

分子量

553.70

Formula

C25H47N9O5

CAS 号

931395-42-5

Sequence Shortening

RIVPA-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Kudrimoti M, et al. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016 Dec 10;239:115-125.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务